To explore if, for locally advanced NSCLC patients whose tumors have high levels of PD-L1, a combination of immunotherapy and a personalized 4-week radiotherapy course could be more effective than cCRT. The gene discussed is CD274; the disease is non-small cell lung carcinoma.